Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway

Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly malignancies with <5% five-year survival rate due to late diagnosis, limited treatment options and chemoresistance. There is thus an urgent unmet clinical need to develop effective anticancer drugs to treat pancreatic cancer. Here,...

詳細記述

保存先:
書誌詳細
出版年:Sci Rep
主要な著者: Wang, Xin, Wu, Xingye, Zhang, Zhonglin, Ma, Chao, Wu, Tingting, Tang, Shengli, Zeng, Zongyue, Huang, Shifeng, Gong, Cheng, Yuan, Chengfu, Zhang, Linghuan, Feng, Yixiao, Huang, Bo, Liu, Wei, Zhang, Bo, Shen, Yi, Luo, Wenping, Wang, Xi, Liu, Bo, Lei, Yan, Ye, Zhenyu, Zhao, Ling, Cao, Daigui, Yang, Lijuan, Chen, Xian, Haydon, Rex C., Luu, Hue H., Peng, Bing, Liu, Xubao, He, Tong-Chuan
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group UK 2018
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6297164/
https://ncbi.nlm.nih.gov/pubmed/30559409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-36214-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料